Information Collection

PART 314: Subparts E through I

IC 184605 under ICR 202412-0910-010 · OMB 0910-0001.

⚠️ Notice: This information collection may be referencing outdated material. More recent filings for OMB 0910-0001 can be found here:

Documents and Forms

Documents and forms in this information collection
Document Name	Document Type
Form FDA 3938 PART 314: Subparts E through I	Form
Form FDA 3938 Drug Master File PART 314: Subparts E through I	Form
0001 Form FDA 3938_instructions_07-12-23.pdf	Instruction
0001 Form FDA 3938_instructions_07-12-23.pdf	Instruction
FDA 3938 Drug Master File 0001 Form FDA 3938_Dyn_Sec_Ext_07-12-23.pdf	Form
FDA 3938 Drug Master File 0001 Form FDA 3938_Dyn_Sec_Ext_07-12-23.pdf	Form

IC Title:

PART 314: Subparts E through I

Agency IC Tracking Number:

CDER

Is this a Common Form? No

IC Status: Unchanged

Obligation to Respond: Mandatory

CFR Citation: 21 CFR 314.200-314.650

Information Collection Instruments:

table that charts list of instruments
Document Type	Form No.	Form Name	Instrument File	URL	Available Electronically?	Can Be Submitted Electronically?	Electronic Capability
Form	FDA 3938				Yes	Yes	Fillable Fileable
Instruction					Yes	Yes	Fillable Fileable

Line of Business: Health

Subfunction: Consumer Health and Safety

Privacy Act System of Records

Title:

FR Citation:

Number of Respondents: 1,826

Number of Respondents for Small Entity: 0

Affected Public: Private Sector

Private Sector: Businesses or other for-profits

Percentage of Respondents Reporting Electronically: 99 %

table that charts list of burden
	Approved	Previously Approved
Annual Number of Responses for this IC	44,338	44,338
Annual IC Time Burden (Hours)	395,012	395,012
Annual IC Cost Burden (Dollars)	0	0

Documents for IC

table that charts IC Documents
Title	Document	Date Uploaded
No associated records found

Blank fields in records indicate information that was not collected or not collected electronically prior to July 2006.

Something went wrong when downloading this file. If you have any questions, please send an email to [email protected].